AU2003284795A1 - Series of recombinant adeno-associated virus useful for inducing rnai pathway and gene therapy - Google Patents

Series of recombinant adeno-associated virus useful for inducing rnai pathway and gene therapy

Info

Publication number
AU2003284795A1
AU2003284795A1 AU2003284795A AU2003284795A AU2003284795A1 AU 2003284795 A1 AU2003284795 A1 AU 2003284795A1 AU 2003284795 A AU2003284795 A AU 2003284795A AU 2003284795 A AU2003284795 A AU 2003284795A AU 2003284795 A1 AU2003284795 A1 AU 2003284795A1
Authority
AU
Australia
Prior art keywords
series
gene therapy
associated virus
recombinant adeno
rnai pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003284795A
Inventor
Xiaoyan Dong
Yunde Hou
Xiaochun Lu
Xin Ma
Xiaobing Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGTC Gene Technology Co Ltd
Original Assignee
AGTC Gene Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AGTC Gene Technology Co Ltd filed Critical AGTC Gene Technology Co Ltd
Publication of AU2003284795A1 publication Critical patent/AU2003284795A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU2003284795A 2002-11-07 2003-11-07 Series of recombinant adeno-associated virus useful for inducing rnai pathway and gene therapy Abandoned AU2003284795A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN02149319.7 2002-11-07
CNA021493197A CN1498964A (en) 2002-11-07 2002-11-07 Serial recombined gland related virus inducible path of RNAi, and utilized in gene therapy
PCT/CN2003/000939 WO2004063380A1 (en) 2002-11-07 2003-11-07 Series of recombinant adeno-associated virus useful for inducing rnai pathway and gene therapy

Publications (1)

Publication Number Publication Date
AU2003284795A1 true AU2003284795A1 (en) 2004-08-10

Family

ID=32686813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003284795A Abandoned AU2003284795A1 (en) 2002-11-07 2003-11-07 Series of recombinant adeno-associated virus useful for inducing rnai pathway and gene therapy

Country Status (3)

Country Link
CN (1) CN1498964A (en)
AU (1) AU2003284795A1 (en)
WO (1) WO2004063380A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781787T3 (en) 2004-08-23 2018-01-31 Sylentis Sau Treatment of eye disorders characterized by an elevated intraocular pressure by sirnas
CN101970051A (en) * 2007-12-31 2011-02-09 纳诺科尔治疗公司 Rna interference for the treatment of heart failure
CN111235150B (en) * 2020-03-11 2020-10-27 苏州世诺生物技术有限公司 shRNA for inhibiting replication of African swine fever virus and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
IL151928A0 (en) * 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
WO2001094605A2 (en) * 2000-06-09 2001-12-13 University Of Florida Research Foundation, Inc. Recombinant aav vectors for gene therapy of obesity

Also Published As

Publication number Publication date
CN1498964A (en) 2004-05-26
WO2004063380A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
AU2003210497A1 (en) Gene delivery system and methods of use
EP1514106A4 (en) Targeted therapeutic proteins
HK1086278A1 (en) Dengue and west nile virus proteins and genes and their therapeutic application
ZA200410229B (en) Administration of therapeutic viruses
IL174938A0 (en) Ceramic armour and method of construction
AU2002320025A1 (en) Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
AU2003225281A1 (en) Materials and methods for prevention and treatment of rna viral diseases
AU2003209226A1 (en) Adiponectin gene therapy
EP1575601A4 (en) Recombinant vaccine viruses expressing il-15 and methods of using the same
AU2003289742A1 (en) Stable therapeutic proteins
AU2002325683A1 (en) Recombinant vector derived from adeno-associated virus for gene therapy
EP1691820A4 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
AU2003287145A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003249659A1 (en) Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2003284795A1 (en) Series of recombinant adeno-associated virus useful for inducing rnai pathway and gene therapy
AU2003290026A1 (en) Immunization of fish with plant-expressed recombinant proteins
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003217956A1 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
AU2003260301A1 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
AU2003279312A1 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003284111A8 (en) Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
AU2002364163A1 (en) USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
AU2003256931A1 (en) USES OF CIRCADIAN GENE mPER2

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase